Cite
Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).
MLA
Terada, Mitsumi, et al. “Phase III Study of Tri-Modality Combination Therapy with Induction Docetaxel plus Cisplatin and 5-Fluorouracil versus Definitive Chemoradiotherapy for Locally Advanced Unresectable Squamous-Cell Carcinoma of the Thoracic Esophagus (JCOG1510: TRIANgLE).” Japanese Journal of Clinical Oncology, vol. 49, no. 11, Dec. 2019, pp. 1055–60. EBSCOhost, https://doi.org/10.1093/jjco/hyz112.
APA
Terada, M., Hara, H., Daiko, H., Mizusawa, J., Kadota, T., Hori, K., Ogawa, H., Ogata, T., Sakanaka, K., Sakamoto, T., Kato, K., & Kitagawa, Y. (2019). Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Japanese Journal of Clinical Oncology, 49(11), 1055–1060. https://doi.org/10.1093/jjco/hyz112
Chicago
Terada, Mitsumi, Hiroki Hara, Hiroyuki Daiko, Junki Mizusawa, Tomohiro Kadota, Keisuke Hori, Hirofumi Ogawa, et al. 2019. “Phase III Study of Tri-Modality Combination Therapy with Induction Docetaxel plus Cisplatin and 5-Fluorouracil versus Definitive Chemoradiotherapy for Locally Advanced Unresectable Squamous-Cell Carcinoma of the Thoracic Esophagus (JCOG1510: TRIANgLE).” Japanese Journal of Clinical Oncology 49 (11): 1055–60. doi:10.1093/jjco/hyz112.